The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
Clinical trial NCT06587425 · RECRUITING
Trial details
- NCT number
- NCT06587425
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-31
- Primary completion
- 2025-07-31
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.